McKesson to Acquire Precision Medicine Group for Approximately $2.25 Billion to Expand Oncology and Biopharma Services McKesson Corporation (NYSE: MCK) has announced a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharmaceutical commercialization…
Pretzel Therapeutics Receives FDA Clearance to Advance PX578 Into Phase 2 Study for POLG-Mediated Mitochondrial Disease Pretzel Therapeutics, Inc., a clinical-stage biotechnology company focused on developing a new generation of medicines designed to restore mitochondrial function, improve cellular energy production…
Precision BioSciences Doses First Patient in Phase 1/2 FUNCTION-DMD Trial of PBGENE-DMD for Duchenne Muscular Dystrophy Precision BioSciences, Inc., a clinical-stage gene editing company developing in vivo therapies for diseases with significant unmet medical needs, has announced that the first…
Charles River Laboratories and Medigen Vaccine Biologics Collaborate to Advance Next-Generation Multivalent Enterovirus Vaccine Charles River Laboratories and Medigen Vaccine Biologics Corp. (MVC) have entered into a strategic collaboration focused on the characterization and validation of the virus seed bank…
Mitochon Pharmaceuticals Receives $1 Million ALS Association Award to Advance MP-101 Clinical Development Mitochon Pharmaceuticals has announced that it has received a $1 million Hoffman ALS Clinical Trial Award from The ALS Association to support the continued clinical development of…
NTx Bio Platform Supports Personalized mRNA Vaccine Manufacturing for Phase 1 Melanoma Trial NTx Bio, a company developing next-generation biomanufacturing technologies, announced that its NTxscribe® CORE platform is being used by researchers at Baylor College of Medicine to manufacture messenger…
Merck and Moderna Report Positive Phase 3 Results for Personalized mRNA Cancer Therapy in Melanoma Merck, known as MSD outside the United States and Canada, and Moderna, Inc. have announced positive topline results from the Phase 3 INTerpath-001 clinical trial…
BeOne Medicines, BeOne Care Foundation and The Max Foundation Renew Partnership to Expand BRUKINSA Access for Patients With CLL BeOne Medicines Ltd., a global oncology company, has announced the renewal of its partnership with the BeOne Care Foundation and The…
Cardio Diagnostics Launches In-House CLIA-Certified Laboratory to Advance Precision Cardiovascular Testing Cardio Diagnostics Holdings, Inc., an artificial intelligence-driven precision cardiovascular medicine company, has announced the official launch of its new high-complexity, Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in Iowa City,…
Enveda Reports Positive Phase 1 Results for ENV-308, an Oral Therapy Designed to Support Long-Term Metabolic Health As the use of GLP-1 medications continues to expand among adults in the United States, growing attention is being directed toward a major…
Ingenia Therapeutics Begins KOSDAQ Trading to Advance Vascular-Targeted Therapy Pipeline Ingenia Therapeutics, a clinical-stage biotechnology company focused on developing next-generation vascular-targeted therapies, has announced that its shares have begun trading on South Korea’s KOSDAQ market, marking a significant milestone in…
InduPro Raises $77 Million Series B and Advances Lead Oncology Program IDP-001 Into Phase 1 Clinical Development InduPro, Inc., a biotechnology company developing a new class of therapeutics based on the spatial organization of proteins on cell surfaces, has announced…